Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hearing that answer, any surfer could tell you that you suck at surfing. I bet you think you’d be a world class surgeon as well.
Primary Completion Date.
December 2024. Was August 2025. And in your most recent posts on this, you conceded you were wrong and conceded the latest given date is probably correct.
But you suck at surfing. DCVax-l is probably about to get its proverbial foot in the door against one of the toughest cancer indications to treat.
Personally, I don’t think a lot of these price prediction downgrades will age well. This is ultimately intended to be a universal cancer vaccine, and it’s almost certainly about to get its proverbial foot in the door via maa approval, and if you price prediction bashers don’t think that makes NWBO more attractive to BP, BO, Institutions and the greater market place, well, I can’t say I wish you luck with that. You guys have done a heck of a job keeping the market cap lid on this puppy, but hopefully your effectiveness days are numbered.
I don’t work on homework assignments for bears and shorts.
Another inaccurate site and you know it. Take that August transaction of Marnix Bosch, it wasn’t a “sale,” it was a disposition of less than 10% of his options/securities to children for estate planning purposes.
Ex was wrong, but for very helpful reasons if you think it through, ex likely dropped an early Christmas present (perhaps unintentionally). In my opinion.
Because fintel sucks at updating?
If, for argument’s sake, the treatment arm already won in the combo trial, it’s likely PFS, which would have huge implications well beyond orphan status indications. And remember, NWBO has the combo patent in Europe and some other jurisdictions as well already that go out to at least 2036.
Because LP is suddenly talking about lots of early response trial designs in the future, I’d guess the DCVAx-l + poly-iclc + Keytruda arm beat control, because Keytruda would help provide the early response dimension to clinical results, imho.
My guess? DSMB.
Hopefully good news. The combo interim results were certainly good, and there has been no serious safety concerns publicized.
It’s really a win win either way for DCVax if the trial ended for efficacy. Either DCVax-l + Keytruda + poly-iclc beat DCVax-l + poly-iclc + placebo, or the other way around.
Not quite a draw Ex. Below were your words before the combo trial completion date was moved up from August 2025 to December 2024. Your post, as they say, did not age well.
I’m not gonna lie. I was originally taken aback when it was moved to August 2025. Ex wins his share of knowledge battles, but his win on that one stung. Now that it is moved back to 2024, I’m cautiously optimistic again. I’ll leave it at that.
The timing expressed at the ASM by LP regarding NICE suggests otherwise.
Won’t be surprising unless you come up with the same number on the 30th.
Have we had this conversation? The reason we may be waiting on filing with NICE, is that without EDEN production cost effectiveness online, NICE might be more likely to reject paying for the treatment. https://www.theguardian.com/science/2017/dec/20/drug-giants-hefty-prices-nhs-vital-medication-pharma-profits
The bears love arguing price of therapy has nothing to do with approval, and while that’s true, winning the approval battle but losing marketing reimbursement would be a time set back, would it not? Therefore, it would appear we are going forward with NICE only when we make them a lower cost offer they can’t refuse. The alternative might be initial reimbursement rejection due to high price, then having to go through a reconsideration.
LP probably doesn’t want to undergo that latter hiccup, particularly since she does not want to create an overpriced paradigm anyway.
(Hopefully, but not assuredly, during the interim, there will be temporary funding available from another source.)
Darn. Thanks.
He’s still management (even though employment contract not renewed), and, imo, that means reporting laws apply to him. I assume he did not convert those twelve million options and sell them, because that would have triggered reporting requirements, and nothing was reported about that. I assume he still has all those options he received as an annuity from his Goldman Charitable Trust.
The law was created for a reason.
The 2010 alternative uptick rule (Rule 201) allows investors to exit long positions before short selling occurs. The rule is triggered when a stock price falls at least 10% in one day. At that point, short selling is permitted if the price is above the current best bid.
This aims to preserve investor confidence and promote market stability during periods of stress and volatility.
All day tomorrow.
When a stock's value drops more than 10%, it triggers what's known as a "circuit breaker," which prohibits short selling for the remainder of that trading day and the following, too. If you want to short a stock with a 10% price drop, the short-sale order must be higher than the bid, making the trade on the uptick.
I don’t think Les converted 12 million options and sold those shares. Why don’t you ask him, and if he did, when? I’m pretty certain the GCT and annuity payment doesn’t let him avoid required reporting. IMO.
More than likely it was a financing, and those involved, aside from the company, likely counted on nothing happening in this short time frame. My guess is everything went according to plan for financiers, shorts and accumulators.
Just my guess, but something could happen so soon now, that competitive loans instead of financings would be less risky post Labor Day until news.
Just spitballing, but a quick spike like that and quick drop to quickly sell shares to investors, leads me to believe the financiers know they are gambling exposure time, being that they can’t hold back courts or regulators from doing their thing, which says to me, any financings and accumulations by other parties is now being done in very condensed time frames.
Or there was a financing, and the pop was then shorted down to then sell off to those who want to accumulate.
I know absolutely nothing about charting, but I’ll still point out that somone on Friday evening threw in an upward price spike so that the price could be pinned down today (and perhaps further) for accumulation. (Even Scotty “bot” at .341 today.) That’s often an accumulation move. Or, alternatively, it could be there was a recent financing. (Which, in a twisted way is still sort of an accumulation maneuver.)
I’m an investor, and you’re a schill. Go start SCHILLHUB.
You’re just trying to throw people off the scent you indirectly schill for another BP.
Oh look, it’s chemo Joe.
Fruit loop.
If the Court has not given a heads up to parties in order to motivate negotiations, I’d opine the court might be waiting to file its MTD decision until school starts back up. That way, (assuming MTD denied) scheduling next steps will not be interrupted by party vacation schedules. Labor Day is notorious for last chance vacations.
I was trying to think about what noninsider ground observations might be happening. Cognate, King’s, various hospitals might be monitored for regulator inspection activity. Simply different/government license plates in Advent’s or Cognate’s parking lots. Recognizable inspectors crossing the pond.
I think runs consolidate. However, I think NWBO, the court and/or regulators could weigh in simply by moving processes forward at some point. That said, I don’t think we’ve had a “run” in any technical sense. More like a spike. I don’t think Friday was a major information point. It would be logical to have a run moving towards fall, but what is logical?
What do you mean by “real world”? Real world evidence? Earth? Non-trial evidence? Please try to think before formulating your questions.
Very strange that “governance” guy doesn’t know how to use quotation marks.
That quote is learningcurve’s.
DCVax-l long term five year survival is real in 13% of patients treated in the phase iii glioblastoma trial. Glioblastoma is exponentially more difficult to treat than B cell lymphoma. Car-T, and Car-T cells wipe out healthy B cells as well as cancerous ones to achieve their temporary effect.
In Glioblastoma, DCVax-l long term survival with poly-iclc appears to be significantly better. The safety and quality of life, and cost is far better for DCVax-l treated patients. Add Csf1r to that mix, and you may be near a cure.
You believe the science behind DCVax-l is respectable and demonstrates signals of efficacy, but you spend ten years here hoping to force its downfall. You won’t succeed, imo.
At the same time you try to argue the science, you intermittently claim you don’t know enough to comment on the science, and claim you are only here to complain about governance. Geesh.